NCT01233505: Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors |
|
|
| Terminated | 1 | 16 | US | veliparib, ABT-888, capecitabine, CAPE, Ro 09-1978/000, Xeloda, oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, pharmacological study, pharmacological studies, laboratory biomarker analysis | National Cancer Institute (NCI) | Adenocarcinoma of the Pancreas, Adenocarcinoma of the Stomach, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ovarian Mucinous Cystadenocarcinoma, Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Gastric Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Gastric Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Unspecified Adult Solid Tumor, Protocol Specific | 10/13 | | | |